Timothy Fennell, PhD, conducts in vitro and in vivo research investigations funded by industrial, commercial, and government clients. He has more than 30 years of experience in mechanistic-based research and is recognized as an expert in biomarkers, particularly in the area of reactive chemicals/metabolites and exposure assessment via protein- and DNA-adduct measurement. His recent research activities in pharmacology include investigations of the pharmacokinetics of potential therapeutic agents and their ability to cross the blood-brain barrier. Dr. Fennell serves as the director of the RTI Center for Nanotechnology Health Implications Research funded by the National Institute of Environmental Health Sciences. Projects in this Center develop lab-based data for cells and rodents exposed to nanoparticles for the construction and validation of physiologically based pharmacokinetic models to provide a firm basis for the informed assessment of health risks associated with exposure to nanoparticles.
Timothy R. Fennell
Director, Analytical Chemistry & Pharmaceutics (ACP)
PhD, Biochemistry, Department of Biochemistry, University of Surrey, Great Britain
BSc, Biochemistry (Honors), Department of Biochemistry, University of Surrey